BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakashima M, Ide K, Kawakami K. Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study. Target Oncol 2019;14:295-306. [PMID: 31093834 DOI: 10.1007/s11523-019-00642-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920936932. [PMID: 32684988 DOI: 10.1177/1758835920936932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]